CHIVAX Trademark

Trademark Overview

On Friday, July 12, 2019, a trademark application was filed for CHIVAX with the United States Patent and Trademark Office. The USPTO has given the CHIVAX trademark a serial number of 88512579. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 26, 2021. This trademark is owned by Virion Therapeutics, LLC. The CHIVAX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, research, development, engineering and testing services focused on vaccine platform technologies; Scientific research in the field of vaccines, namely, research and development of cell preparations, cellular vaccines, and therapeutics for the treatment of cancer and infectious diseases; Research and development of technology in the field of immunotherapy platforms for manufacturing t-cell based therapeutics for cancer and infectious diseases
chivax

General Information

Serial Number88512579
Word MarkCHIVAX
Filing DateFriday, July 12, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 26, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 28, 2020

Trademark Statements

Goods and ServicesResearch and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, research, development, engineering and testing services focused on vaccine platform technologies; Scientific research in the field of vaccines, namely, research and development of cell preparations, cellular vaccines, and therapeutics for the treatment of cancer and infectious diseases; Research and development of technology in the field of immunotherapy platforms for manufacturing t-cell based therapeutics for cancer and infectious diseases

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, July 18, 2019
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVirion Therapeutics, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNewark, DE 19711
Party NameVirion Therapeutics, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNewark, DE 19711

Trademark Events

Event DateEvent Description
Monday, April 26, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 26, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 22, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 28, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 28, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 8, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, June 22, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, June 20, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, June 20, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 17, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, June 10, 2020NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
Wednesday, June 10, 2020ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
Wednesday, June 10, 2020ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
Wednesday, June 10, 2020ASSIGNED TO EXAMINER
Tuesday, June 2, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 2, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 29, 2020ASSIGNED TO LIE
Thursday, May 21, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, March 18, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, March 18, 2020FINAL REFUSAL E-MAILED
Wednesday, March 18, 2020FINAL REFUSAL WRITTEN
Thursday, March 5, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, March 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 27, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 27, 2019NON-FINAL ACTION E-MAILED
Friday, September 27, 2019NON-FINAL ACTION WRITTEN
Friday, September 27, 2019ASSIGNED TO EXAMINER
Thursday, July 18, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, July 16, 2019NEW APPLICATION ENTERED IN TRAM

Related Keywords

chivax research development vaccines infectious diseases cell cancer therapeutics field namely